Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SPH4336 in HR+/HER2- breast cancer post-CDK4/6 inhibitor progression
NCT05860465Phase 3Recruiting
- Sponsor
- Shanghai Pharmaceuticals Holding Co Ltd
- Start
- Sep 2023
- Primary completion
- Dec 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in breast cancer comparing SPH4336 + Endocrine Therapy with Placebo + Endocrine Therapy (2 arms). Primary endpoints: Objective Response Rate at 3 years and Progression-Free Survival at 3 years. Started Sep 2023; status: recruiting.
02
Drugs
SPH4336
03
Conditions
breast cancer
Beyond the preview
Go deeper on NCT05860465.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05860465.